Flex Pharma Reports Year End 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Flex Pharma (FLKS) PT Lowered to $9 at Jefferies Following 4Q
March 9, 2017 7:37 AM ESTJefferies lowered its price target on Flex Pharma (NASDAQ: FLKS) to $9.00 (from $11.00) while maintaining a Buy rating. FLKS reported EPS and HotShot sales of -$0.48 vs. -$0.62 estimate and $0.3M vs. $0.2M, respectively, with slightly lower opex of $8.3M vs. $10.6M... More
Flex Pharma (FLKS) Tops Q4 EPS by 18c
March 8, 2017 7:02 AM ESTFlex Pharma (NASDAQ: FLKS) reported Q4 EPS of ($0.48), $0.18 better than the analyst estimate of ($0.66).
For earnings history and earnings-related data on Flex Pharma (FLKS) click here.
... More